Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ascentage Pharma Group International ( (HK:6855) ) has shared an update.
Ascentage Pharma Group International has strengthened its corporate governance and R&D oversight by revising the composition of its nomination committee, appointing Dr. Debra Yu as an additional member, and naming existing independent non-executive director Dr. David Sidransky as lead independent non-executive director to enhance communication between the board, management, and shareholders. The company has also created a dedicated research and development committee comprising scientific and business experts to oversee pipeline strategy and risk management, and it has clarified that a proposed grant of restricted share units and options to substantial shareholder Dr. Zhai Yifan will require independent shareholder approval under Hong Kong listing rules, with part of her RSU vesting deferred until after that vote.
The most recent analyst rating on (HK:6855) stock is a Hold with a HK$63.00 price target. To see the full list of analyst forecasts on Ascentage Pharma Group International stock, see the HK:6855 Stock Forecast page.
More about Ascentage Pharma Group International
Ascentage Pharma Group International is a Hong Kong–listed biopharmaceutical company focused on research and development of innovative therapies, with its operations overseen by a board that includes scientists, physicians, and industry experts guiding its R&D strategy and corporate governance structure.
Average Trading Volume: 1,934,841
Technical Sentiment Signal: Hold
Current Market Cap: HK$19.85B
See more insights into 6855 stock on TipRanks’ Stock Analysis page.